Blockchain Registration Transaction Record

Tonix Data Reveals Heavy Fibromyalgia Burden; TONMYA Launch Nears

Tonix Pharmaceuticals presents real-world data at ISPOR showing high comorbidity and cost burden of fibromyalgia, as TONMYA launch approaches. Read more at InvestorWire.

For the millions of Americans suffering from fibromyalgia, this news underscores the persistent challenges in managing the condition, including high rates of comorbidities and costly healthcare utilization. Tonix's TONMYA represents a potential new treatment option after more than a decade without innovation, which could improve quality of life and reduce economic strain on patients and the healthcare system. Investors should note the company's progress toward commercialization, as successful launch could address a significant unmet medical need and drive growth.